Transcranial Magnetic Stimulator - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The transcranial magnetic stimulator market size is expected to grow from USD 1.44 billion in 2025 to USD 1.58 billion in 2026 and is forecast to reach USD 2.48 billion by 2031 at 9.45% CAGR over 2026-2031. This report is Segmented by Product Type (Deep TMS, Repetitive TMS, Accelerated TMS, and More), Application (Depression, Alzheimer's Disease, and More), Age Group (Adults, and More), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Transcranial Magnetic Stimulator Market Trends and Insights

Rising Prevalence of Treatment-Resistant Depression & Expanded FDA Clearances

Treatment-resistant depression affects about 30% of major depressive disorder patients, creating an urgently addressable pool for TMS therapy. NeuroStar Advanced Therapy’s 2024 FDA clearance for adolescents aged 15-21 marked the first non-pharmacological option for this group and achieved 78% clinical improvement in a 1,169-patient cohort. BrainsWay subsequently received an expanded label for late-life depression, supporting broader geriatric coverage. As major insurers mirrored these FDA decisions, covered lives multiplied and reimbursement friction declined.

Rapidly Aging Population Elevating Neurodegenerative Disease Burden

The rising share of citizens aged 65 and above in Europe, North America, and parts of Asia has intensified demand for disease-modifying interventions. A 52-week personalized repetitive TMS protocol targeting the precuneus slowed cognitive decline in mild-to-moderate Alzheimer’s cases as evidenced by improved Clinical Dementia Rating scores. In parallel, 10 days of rTMS improved motor function in Parkinson’s disease by modulating inflammatory regulatory T-cells, maintaining benefit for 40 days post-treatment. These clinical gains, coupled with the transcranial magnetic stimulator market’s maturing reimbursement pathways, reinforce the modality’s neurological expansion.

Preference for Electroconvulsive Therapy (ECT) & Deep Brain Stimulation (DBS)

ECT maintains superior remission rates in severe mood disorders and can limit TMS adoption in tertiary psychiatric centers. The ASCERTAIN-TRD trial reported a mean MADRS score improvement of -17.39 for rTMS versus -13.22 for pharmacological switching, an important benefit yet still below established ECT benchmarks. Moreover, manufacturers of implantable DBS systems such as the Vercise PC list TMS as a contraindication because of interference risks, obliging clinicians to choose one modality per patient. Closed-loop DBS innovations with real-time neural feedback widen this performance gap.

Other drivers and restraints analyzed in the detailed report include:

• Favorable Insurance Reimbursement in Developed Nations
• AI-Guided Coil Positioning & Closed-Loop Stimulation Enhancing Outcomes
• High Capital Cost & Technician Shortage

Segment Analysis

Repetitive TMS held a 57.71% transcranial magnetic stimulator market share in 2025, reflecting three decades of clinical validation and the breadth of FDA-cleared psychiatric indications. Commercial familiarity, favorable reimbursement, and declining device prices keep the modality a default entry point for new providers. Deep TMS nevertheless records a 13.29% CAGR, the fastest within the segment hierarchy. Its H-coil architecture penetrates limbic and subcortical areas unreachable by figure-8 coils, supporting approvals for depression, obsessive-compulsive disorder, and nicotine addiction. Therapeutic interest is further reinforced as real-world registries link deeper stimulation targets to reduced relapse rates in treatment-resistant cohorts.

Accelerated protocols are reshaping clinical throughput. Stanford’s SAINT regimen compresses 50 sessions into 5 days, a six-fold reduction in patient visits and associated indirect costs. Concurrently, theta-burst stimulation produces equivalent outcomes to standard 10 Hz series in one-third the time, supporting operational scalability. Navigated TMS adds imaging data to coil positioning, thereby reducing outcome variability. Finally, R&D activity in closed-loop and multi-focal stimulation promises dynamic, patient-specific waveform adjustments aligned to cortical excitability measured in real time. Combined, these sub-segments show how therapeutic innovation continues to widen the transcranial magnetic stimulator market opportunity.

Depression kept a 45.05% slice of the transcranial magnetic stimulator market size in 2025, buoyed by robust reimbursement, extensive safety history, and over 6.9 million delivered treatments worldwide. Despite its central role, sentiment is shifting toward neurodegenerative targets. Alzheimer’s disease posts a 16.61% CAGR thanks to data showing that precuneus-targeted repetitive TMS slows cognitive decline relative to control arms. Health-technology-assessment agencies now factor these results into coverage discussions, accelerating uptake.

Parkinson’s disease benefits from adjunctive rTMS protocols that dampen neuro-inflammation and enhance cortical-subcortical connectivity, delivering measurable motor-score improvements for up to 40 days. Chronic pain applications expand beyond neuropathic indications into fibromyalgia, while stroke-rehabilitation trials find theta-burst strategies promoting motor-cortex plasticity superior to standard physiotherapy alone. OCD remains a steady niche courtesy of both repetitive and deep TMS FDA approvals. The overall breadth of indications buffers revenue streams and cushions the transcranial magnetic stimulator market against reimbursement or clinical-guideline shifts in any single disease area.

Complete Report Scope:

• By Product Type
  • Deep TMS
  • Repetitive TMS
  • Accelerated TMS
  • Theta-Burst Stimulation
  • Navigated TMS
  • Other Types
• By Application
  • Depression
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Epilepsy
  • Chronic Pain
  • Obsessive-Compulsive Disorder
  • Stroke Rehabilitation
  • Other Applications
• By Age Group
  • Adults
  • Pediatric & Adolescents
  • Geriatric
• By End User
  • Hospitals
  • Specialty Clinics
  • Research & Academic Institutes
  • Home-Care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 44.58% revenue leadership in 2025 owing to early FDA approvals, broad insurance coverage, and concentrated manufacturer headquarters. Stable reimbursement, a mature clinical-research ecosystem, and the growing share of service-based TMS networks underpin steady procedure volumes. The United States also pioneers novel payment models, including bundled outpatient episodes, that align incentives for efficient care delivery.

Europe holds the second-largest revenue base, supported by CE-marked devices and harmonized regulations under the Medical Device Regulation framework. Several member states have integrated TMS into national guidelines for depression and OCD, facilitating regional convergence. Reimbursement heterogeneity persists, but high-income nations such as Germany and France reimburse up to 30 daily sessions per index course, reinforcing adoption momentum.

Asia-Pacific is the transcranial magnetic stimulator market’s fastest-growing region at 12.05% CAGR. Japan’s specialized TMS clinics demonstrate high-volume models aided by health-insurance reimbursement. China’s hospital-modernization drive and domestic manufacturing capacity reduce acquisition costs, while private-health spend in India unlocks demand among urban populations. South America and the Middle East & Africa follow in early-stage growth corridors, where neurological disease burden rises against expanding tertiary-care capacity.

List of Companies Covered in this Report:

• BrainsWay Ltd.
• Magstim
• Neuronetics (NeuroStar)
• MagVenture
• Nexstim Plc
• CloudTMS (Neuronavigation)
• Apollo Health
• YINGCHI (Brain Ultimate)
• Brainsight (Rogue Research)
• eNeura Inc.
• TMS Neuro Solutions
• Neurosoft
• REMED Co. Ltd.
• ANT Neuro
• Mag & More GmbH
• MST Solutions
• Salience TMS
• Fischer Wallace Labs
• Monteris Medical
• StimSherpa

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support